IZCZ-3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

IZCZ-3  纯度: 99.45%

IZCZ-3 是有效的 c-MYC 转录抑制剂，具有抗肿瘤活性。

IZCZ-3

IZCZ-3 Chemical Structure

CAS No. : 2223019-53-0

规格 价格 是否有货 数量
5 mg ￥4000 In-stock
10 mg ￥6800 In-stock
50 mg ￥19500 In-stock
100 mg ￥29000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

IZCZ-3 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus

生物活性

IZCZ-3 is a potent c-MYC transcription inhibitor with antitumor activity[1].

IC50 & Target

c-MYC transcription[1]
体外研究
(In Vitro)

IZCZ-3 (2.1 μM-15.9 μM; 24 hours) significantly inhibits SiHa, HeLa, Huh7, and A375 cancer cell proliferation (IC50s of 3.3, 2.1，4.1, and 4.2 μM, respectively). IZCZ-3 induces only weak growth inhibition in the BJ fibroblasts (IC50=15.9 μM) and mouse mesangial cells (IC50=15.6 μM), suggesting that IZCZ-3 is more effective against cancer cells than against c-MYC-independent normal cells[1].
IZCZ-3 (0-5 μM; 12 hours) induces an apparent accumulation of cells in the G0/G1 phase in SiHa cells in a dose-dependent manner[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: SiHa, HeLa, Huh7, and A375 cancer cells (with overexpression of c-MYC protein) and in normal BJ fibroblasts and primary cultured mouse mesangial cells (with relatively low expression of c-MYC protein).
Concentration: 2.1 μM-15.9 μM
Incubation Time: 24 hours
Result: IC50s of 3.3, 2.1，4.1, and 4.2 μM for SiHa, HeLa, Huh7, and A375 cancer cells; IC50s of 15.9 μM and 15.6 μM for BJ fibroblasts and mouse mesangial cells.

Cell Cycle Analysis[1]

Cell Line: SiHa cells
Concentration: 0, 1.25, 2.5, and 5 μM
Incubation Time: 12 hours
Result: Induced an apparent accumulation of cells in the G0/G1 phase (increasing from 61% to 70%) in a dose-dependent manner.

体内研究
(In Vivo)

IZCZ-3 (20, 10, and 5 mg/kg; intraperitoneally; every other day for 24 days) inhibits tumor growth in BALB/c nude mice with SiHa human cervical squamous cancer xenograft[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice (5 weeks old) bearing SiHa human cervical squamous cancer xenograft model[1]
Dosage: 20, 10, and 5 mg/kg
Administration: Treated intraperitoneally; every other day for 24 days
Result: Treatment with 20, 10, and 5 mg/kg resulted in a significant reduction in tumor weight with tumor growth inhibition (TGI) of 69%, 64%, and 57%, respectively. Displayed time-dependent inhibition of tumor growth.

分子量

715.93

Formula

C46H49N7O
CAS 号

2223019-53-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 5 mg/mL (6.98 mM; ultrasonic and warming and heat to 80°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.3968 mL 6.9839 mL 13.9678 mL
5 mM 0.2794 mL 1.3968 mL 2.7936 mL
10 mM — — —

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Hu MH, et al. Discovery of a New Four-Leaf Clover-Like Ligand as a Potent c-MYC Transcription Inhibitor Specifically Targeting the Promoter G-Quadruplex. J Med Chem. 2018 Mar 22;61(6):2447-2459.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务